DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its fourth quarter 2021 financial results after market close on March 14, 2022. A live conference call to discuss these results and provide a business update will take place on March 15, 2022, at 7:00 AM CT. Interested parties can participate via dial-in or webcast. DiaMedica is focused on novel treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.

Positive

• DM199 is a novel therapeutic candidate with potential for treating serious diseases.
• Company's focus on neurological disorders and kidney diseases may attract investor interest.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14^th. DiaMedica will host a live conference call on Tuesday, March 15^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date:	Tuesday, March 15, 2022
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://events.q4inc.com/attendee/778628289
Dial In:	(888) 440-4368
Conference ID:	4814247

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until March 22, 2022, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005373/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics announce its fourth quarter 2021 financial results?

DiaMedica Therapeutics will announce its fourth quarter 2021 financial results on March 14, 2022.

What time is the DiaMedica Therapeutics conference call?

The conference call is scheduled for March 15, 2022, at 7:00 AM CT.

How can I access the DiaMedica Therapeutics conference call?

You can access the conference call by dialing (888) 440-4368 or via the webcast link provided in the press release.

What is DiaMedica Therapeutics' lead candidate?

DiaMedica's lead candidate is DM199, aimed at treating acute ischemic stroke and chronic kidney disease.